⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3491173 | 0.97 | — | — | |
| SCHEMBL4264802 | 0.82 | — | — | |
| SCHEMBL9651246 | 0.80 | — | — | |
| SCHEMBL14641650 | 0.79 | LMNA (0.31) | — | |
| SCHEMBL5126821 | 0.78 | CES2 (0.56) | — | |
| SCHEMBL1365133 | 0.78 | CES2 (0.56) | — | |
| SCHEMBL20648076 | 0.78 | CES2 (0.56) | — | |
| SCHEMBL13903246 | 0.78 | CES2 (0.56) | — | |
| SCHEMBL1257720 | 0.78 | CES2 (0.56) | — | |
| SCHEMBL1367103 | 0.78 | CES2 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263502-B1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2024-12-25 | — | — | EP | claimed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | claimed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | claimed |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | claimed |
| EP-1534693-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004022523-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-20240139190-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-02 | — | — | US | disclosed |
| WO-2024042313-A1 | COMPOUNDS | UNIVERSITY OF SOUTHAMPTON (GB) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023213874-A1 | COMBINED LACTATE AND KETONE BODY ESTERS FOR MEDICAL AND NUTRITIONAL USE | AARHUS UNIVERSITET (DK) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023211205-A1 | METHOD FOR PREPARATION OF COMPOUND POSSESSING 5-PENTYLFURFURAL (5-PF) STRUCTURE AND USE THEREOF | (주)퓨젠바이오 | 2023-11-02 | — | — | WO | disclosed |
| EP-4181964-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | Mc SAF (FR) | 2023-05-24 | — | — | EP | disclosed |
| EP-4183777-A1 | APPLICATION OF COMPOSITION FOR PLATELET DISAGGREGATION, DISAGGREGATION REAGENT AND DISAGGREGATION METHOD | Shenzhen Mindray Bio-Medical Electronics Co., Ltd (CN) | 2023-05-24 | — | — | EP | disclosed |
| EP-4149928-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2023-03-22 | — | — | EP | disclosed |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060194817-A1 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2004026848-A1 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPERATION AND THEIR USE AS ANTIMYCOBACTERIAL AGENTS | LUPIN LIMITED (IN) | 2004-04-01 | — | — | WO | disclosed |
| EP-0230771-A2 | Pyran derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-08-05 | — | — | EP | disclosed |